The objective of this study is to assess the market potential of current testing areas pertaining to the area of genetics such as diagnostic testing/screeening, relationship testing and predictive testing. Revenue forecast has been provided for 2010-2018 for each segment within the United Kingdom, Germany, France, Italy, Spain, Scandinavia and Benelux. Regulations pertaining to genetic testing in Western European countries have been discussed. A comprehensive list of 90 commercial service providers has been provided.
Market Overview—Key Barriers
There are more than XXXXX laboratories or research centres in Europe practising genetic testing/screening under different settings governed by different policies.
Today, more than XXXXX rare diseases can be tested. There is a lack of centralised and uniform information about the services offered.
The network groups are highly disorganised. There is a lack of harmonised and standardised proficiency testing and external quality providers (PT/EQA).
There are limited ISO-accredited labs.
There are restrictions in health insurance coverage policies and limited analytical and clinical validation tests.
Owing to a diverse regulatory environment, there is insufficient counselling and lack of harmonised group.
Genetic test results are often inaccurate, and hence the shut down of commercial service laboratories poses another potential threat.
Electronic Access - Single User Fulfilled By Publisher
Electronic Access - Global Site License Fulfilled By Publisher